Despite 330 pipeline products, stem cell therapies face commercial challenges
The stem cells field is still surrounded by a wide variety of obstacles, most notably the high cost of research, according to key opinion leaders.
While steady progress in clinical research and increasing evidence of product effectiveness are significant driving factors for growth in the stem cell therapies market, a number of obstacles remain before they become widely commercially viable, according to business intelligence provider GBI Research.
The company’s latest report — Stem Cell Therapies – Global Trends in the Competitive, Technological and R&D Landscape — states that the stem cell therapy pipeline as a whole is relatively large, with 330 products in active development across all stages. Indeed, R&D within the sector is gaining momentum as candidates move into clinical development, and the results of clinical studies become apparent, clarifying the therapeutic potential of stem cell therapy.
Rodrigo Gutierrez Gamboa, Managing Analyst for GBI Research, states: “The stem cell space provides therapeutic potential in indications where current pharmacological and surgical treatment options are ineffective. However, there remains a significant divide between the number of stem cell therapeutic applications currently available for patients and the number of research programs investigating the wider medical applications of stem-cell-based therapies.
“Stem cells are currently being used for a modest variety of indications, with skin and blood stem cells representing the majority of therapeutic uses. The stem cell industry is pursuing a broad base of therapeutic applications, and this is evident in the R&D efforts observed in the sector, as over 15 therapy areas are being targeted by the stem cell industry in over 1,000 clinical trials.”
Despite promising recent developments within the field of stem cell technology, converting its scientific potential into real therapeutic value still represents a significant challenge.
According to GBI Research’s survey of key opinion leaders, the stem cells field is still surrounded by a wide variety of obstacles, most notably the high cost of research, which survey participants stated was the biggest factor limiting stem cell progress.
Gutierrez Gamboa concludes: “Manufacturers will need to adopt novel strategies to realize their full potential. It is likely that manufacturing methodologies will use partially or fully automated systems in future approaches, in order to improve yield, purity and cost-effectiveness.
“There have been good strides made by stem cell manufacturing companies, such as those made by Cynata Therapeutics, which is implementing innovative manufacturing methods to generate robust, consistent and inexpensive stem cells. Such companies are pointing towards a promising outlook in this regard.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance